{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:09:03Z","timestamp":1791389343238,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["Z2022037"],"award-info":[{"award-number":["Z2022037"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SKYD2022067"],"award-info":[{"award-number":["SKYD2022067"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070793"],"award-info":[{"award-number":["32070793"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270191"],"award-info":[{"award-number":["82270191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117198","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T15:36:01Z","timestamp":1753803361000},"page":"117198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Targeting N6-methyladenosine demethylase FTO overcomes osimertinib resistance by inducing G0\/G1 phase arrest in an m6A-dependent manner in lung adenocarcinoma"],"prefix":"10.1016","volume":"242","author":[{"given":"Jun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengru","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8109-056X","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117198_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.117198_b0010","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D\u2019Addario","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0015","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, Molecular Epidemiology Study of EGFR Mutations in asian patients with Advanced Non\u2013Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0040","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR -Mutated Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0050","doi-asserted-by":"crossref","first-page":"v921","DOI":"10.1093\/annonc\/mdz394.083","article-title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","volume":"30","author":"Gray","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0055","doi-asserted-by":"crossref","first-page":"ix177","DOI":"10.1093\/annonc\/mdy483.007","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Cho","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular Biomarkers of Disease Outcomes and Mechanisms of acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0065","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117198_b0070","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in patients with EGFR T790M-positive Lung Cancer and acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0075","article-title":"Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO Precis","volume":"3","author":"Suzawa","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2025.117198_b0080","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1038\/s41467-022-33210-2","article-title":"Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117198_b0085","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117198_b0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-018-0538-8","article-title":"mRNA circularization by METTL3\u2013eIF3h enhances translation and promotes oncogenesis","volume":"561","author":"Choe","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117198_b0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12935-024-03250-3","article-title":"METTL14 enhances the m6A modification level of lncRNA MSTRG.292666.16 to promote the progression of non-small cell lung cancer","volume":"24","author":"Ji","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2025.117198_b0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41388-024-02992-8","article-title":"N6-methyladenosine demethyltransferase FTO mediated m6A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis","volume":"43","author":"Xu","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117198_b0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13046-024-03073-0","article-title":"ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages","volume":"43","author":"Hua","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117198_b0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41416-023-02246-6","article-title":"The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy","volume":"129","author":"Diao","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117198_b0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41419-022-05050-x","article-title":"m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117198_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-022-01519-7","article-title":"Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma","volume":"21","author":"Song","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117198_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-023-01811-0","article-title":"Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117198_b0130","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cmet.2014.09.010","article-title":"Obesity and FTO: changing Focus at a complex Locus","volume":"20","author":"Tung","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2025.117198_b0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41420-022-01125-y","article-title":"Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma","volume":"8","author":"Ning","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bcp.2025.117198_b0140","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41419-021-03739-z","article-title":"WNT\/\u03b2-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117198_b0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1541-7786.MCR-20-0541","article-title":"Exosomal delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner","volume":"19","author":"Xiao","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117198_b0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nprot.2006.37","article-title":"Production and purification of lentiviral vectors","volume":"1","author":"Tiscornia","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2025.117198_b0155","article-title":"Growth arrest specific 2 is Up-Regulated in Chronic Myeloid Leukemia Cells and Required for their growth","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117198_b0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","article-title":"Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia","volume":"35","author":"Huang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117198_b0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cac2.12393","article-title":"Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?","volume":"43","author":"Feng","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bcp.2025.117198_b0170","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117198_b0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","article-title":"Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib","volume":"12","author":"Ho","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2025.117198_b0180","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/nu10111600","article-title":"Fat Mass and Obesity Associated (FTO) Gene and Hepatic Glucose and Lipid Metabolism","volume":"10","author":"Mizuno","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2025.117198_b0185","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.arr.2011.12.003","article-title":"Is obesity linked to aging?","volume":"11","author":"Tzanetakou","year":"2012","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2025.117198_b0190","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/ng.713","article-title":"Overexpression of Fto leads to increased food intake and results in obesity","volume":"42","author":"Church","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2025.117198_b0195","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","article-title":"N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO","volume":"7","author":"Jia","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117198_b0200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12964-023-01343-6","article-title":"FTO facilitates cancer metastasis by modifying the m6A level of FAP to induce integrin\/FAK signaling in non-small cell lung cancer","volume":"21","author":"Gao","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2025.117198_b0205","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.jbc.2022.101563","article-title":"m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis","volume":"298","author":"Gao","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117198_b0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.omto.2021.04.011","article-title":"m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer","volume":"21","author":"Wang","year":"2021","journal-title":"Mol Ther - Oncolytics"},{"key":"10.1016\/j.bcp.2025.117198_b0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11010-023-04748-6","article-title":"LncRNA GAS5 regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1\/BRD4 axis","volume":"479","author":"Fu","year":"2024","journal-title":"Mol. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117198_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.31296","article-title":"FTO blocks RNA translational activity via the loss of N6\u2010methyladenosine methylation at 5\u2032 UTR regulated by RBM5 in cisplatin\u2010resistant NSCLC","volume":"239","author":"Li","year":"2024","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2025.117198_b0225","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s42003-023-04889-w","article-title":"3-phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib","volume":"6","author":"Meraz","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bcp.2025.117198_b0230","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.bcp.2008.02.013","article-title":"Fluoxetine mediates G0\/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1","volume":"75","author":"Krishnan","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117198_b0235","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/ph17121623","article-title":"Repurposing osimertinib and gedatolisib for glioblastoma treatment: evidence of synergistic effects in an in vitro phenotypic study","volume":"17","author":"De S\u00e3o Jos\u00e9","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2025.117198_b0240","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117198_b0245","doi-asserted-by":"crossref","first-page":"100911","DOI":"10.1016\/j.xcrm.2022.100911","article-title":"Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2025.117198_b0250","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling Clinical responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117198_b0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1078-0432.CCR-22-2180","article-title":"Preclinical Study of a Biparatopic METxMET Antibody\u2013Drug Conjugate, REGN5093-M114, Overcomes MET-driven acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC","volume":"29","author":"Oh","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225004630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225004630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T08:31:19Z","timestamp":1761381079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225004630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"alternative-id":["S0006295225004630"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117198","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting N6-methyladenosine demethylase FTO overcomes osimertinib resistance by inducing G0\/G1 phase arrest in an m6A-dependent manner in lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117198"}}